These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16567060)

  • 1. Regulatory challenges for new formulations of controlled substances in today's environment.
    McCormick CG
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S63-7. PubMed ID: 16567060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse deterrent formulations and the Controlled Substances Act (CSA).
    Sapienza FL
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S23-30. PubMed ID: 16529882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research design strategies to evaluate the impact of formulations on abuse liability.
    McColl S; Sellers EM
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S52-62. PubMed ID: 16554125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk management and post-marketing surveillance of CNS drugs.
    Henningfield JE; Schuster CR
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation considerations for the development of medications with abuse potential.
    Mansbach RS; Moore RA
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of opioid formulations with limited diversion and abuse potential.
    Fudala PJ; Johnson RE
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S40-7. PubMed ID: 16564141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principles of assessment of abuse liability: US legal framework and regulatory environment.
    Rocha BA
    Behav Pharmacol; 2013 Sep; 24(5-6):403-9. PubMed ID: 23820327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet.
    Cone EJ
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S31-9. PubMed ID: 16458455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing abuse liability during drug development: changing standards and expectations.
    Schoedel KA; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
    Wright C; Schnoll S; Bernstein D
    Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report.
    Grudzinskas C; Balster RL; Gorodetzky CW; Griffiths RR; Henningfield JE; Johanson CE; Mansbach RS; McCormick CG; Schnoll SH; Strain EC; Wright C
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S77-82. PubMed ID: 16580154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Diversion of Ultram, Ultracet, and generic tramadol HCL.
    Inciardi JA; Cicero TJ; Munoz A; Adams EH; Geller A; Senay EC; Woody GE
    J Addict Dis; 2006; 25(2):53-8. PubMed ID: 16785220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is being done to address the new drug epidemic?
    Dekker AH
    J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES21-6. PubMed ID: 17908827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Debating the Controlled Substances Act.
    Spillane JF
    Drug Alcohol Depend; 2004 Oct; 76(1):17-29. PubMed ID: 15380285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designer drugs: a medicinal chemistry perspective.
    Carroll FI; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA
    Ann N Y Acad Sci; 2012 Feb; 1248():18-38. PubMed ID: 22092008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 Jun; 70(120):36338-44. PubMed ID: 15973789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Controlled Substances Act: how a "big tent" reform became a punitive drug law.
    Courtwright DT
    Drug Alcohol Depend; 2004 Oct; 76(1):9-15. PubMed ID: 15380284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the South American Agreement on Narcotic Drugs and Psychotropic Substances in the fight against illicit drug trafficking.
    Cagliotti CN
    Bull Narc; 1983; 35(4):83-95. PubMed ID: 6563931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk identification, risk assessment, and risk management of abusable drug formulations.
    Wright C; Kramer ED; Zalman MA; Smith MY; Haddox JD
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S68-76. PubMed ID: 16581201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.